Hepatitis C Virus Treatment in HIV



Since the introduction of highly active antiretroviral therapy (HAART), HIV has been successfully converted into a chronic condition. In place of traditional opportunistic infections, Hepatitis C Virus (HCV)–related liver disease has emerged as a significant cause of morbidity and mortality in HIV infected persons [1]. HIV–HCV coinfected patients have an accelerated rate of fibrosis, developing cirrhosis more rapidly than those with HCV alone [2]. Among those with HCVrelated decompensated liver disease, HIV coinfection also increases liver–related mortality [3]. Efforts to treat HCV are, therefore, warranted to forestall these complications.


Sustained Virologic Response Sustained Virologic Response Rate Rapid Virologic Response Early Virological Response Prior Nonresponder 


  1. 1.
    Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;33(2):240–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30(4):1054–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Pineda JA, Romero-Gómez M, Díaz-García F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology. 2005;41(4):779–89.PubMedCrossRefGoogle Scholar
  4. 4.
    Maylin S, Martinot-Peignoux M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology. 2008;135(3):821–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Berenguer J, Alvarez-Pellicer J, Martín PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009;50(2):407–13.PubMedCrossRefGoogle Scholar
  6. 6.
    Bonnard P, Lescure FX, Amiel C, et al. Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count. J Viral Hepat. 2007;14(11):806–11.PubMedCrossRefGoogle Scholar
  7. 7.
    Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97(10):2614–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Shaheen AA, Myers RP. Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection. HIV Clin Trials. 2008;9(1):43–51.PubMedCrossRefGoogle Scholar
  9. 9.
    Vergara S, Macías J, Rivero A, et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis. 2007;45(8):969–74.PubMedCrossRefGoogle Scholar
  10. 10.
    Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS. 2007;21(9):1073–89.PubMedCrossRefGoogle Scholar
  11. 11.
    Uberti-foppa C, Bona AD, Galli L, et al. Liver fibrosis in HIV-positive patients. Liver. 2006;41(1):63–7.Google Scholar
  12. 12.
    Sánchez-Conde M, Berenguer J, Miralles P, et al. Liver biopsy findings for HIV-infected patients with chronic hepatitis C and persistently normal levels of alanine aminotransferase. Clin Infect Dis. 2006;43(5):640–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Martin-Carbonero L, de Ledinghen V, Moreno A, et al. Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection. J Viral Hepat. 2009;16(11):790–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005;436(7053):967–72.PubMedCrossRefGoogle Scholar
  15. 15.
    Carithers RL, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology. 1997;26(3 Suppl 1):83S–88.PubMedCrossRefGoogle Scholar
  16. 16.
    McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339(21):1485–92.PubMedCrossRefGoogle Scholar
  17. 17.
    Feld JJ, Lutchman GA, Heller T, et al. Ribavirin improves early responses to peginterferon through enhanced interferon signaling. Gastroenterology. 2010;139(1):154–62.e4.PubMedCrossRefGoogle Scholar
  18. 18.
    Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology. 2006;130(1):231–64. quiz 214–7.PubMedCrossRefGoogle Scholar
  19. 19.
    McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580–93.PubMedCrossRefGoogle Scholar
  20. 20.
    Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351(5):451–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292(23):2839–48.PubMedCrossRefGoogle Scholar
  22. 22.
    Núñez M, Miralles C, Berdún MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses. 2007;23(8):972–82.PubMedCrossRefGoogle Scholar
  23. 23.
    Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351(5):438–50.PubMedCrossRefGoogle Scholar
  24. 24.
    Berenguer J, González-García J, López-Aldeguer J, et al. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. J Antimicrob Chemother. 2009;63(6):1256–63.PubMedCrossRefGoogle Scholar
  25. 25.
    Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346–55.PubMedGoogle Scholar
  26. 26.
    Ramos B, Núñez M, Rendón A, et al. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. J Viral Hepat. 2007;14(6):387–91.PubMedCrossRefGoogle Scholar
  27. 27.
    Morello J, Soriano V, Barreiro P, et al. Plasma ribavirin trough concentrations at week 4 predict HCV relapse in HIV/HCV-coinfected patients treated for chronic hepatitis C. Antimicrob Agents Chemother. 2010;54(4):1647–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Rodriguez-Torres M, Slim J, Bhatti L, et al. Standard versus high dose ribavirin in combination with peginterferon alfa-2a (40 kD) in genotype 1 (G1) HCV patients coinfected with HIV: final results of the PARADIGM study. Program and abstracts of the 60th Annual Meeting of the American Association for the Study of Liver Diseases; October 30–November 3, 2009; Boston, MA; 2009. Abstract 1561.Google Scholar
  29. 29.
    Ferenci P, Laferl H, Scherzer T, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology. 2008;135(2):451–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Van den Eynde E, Crespo M, Esteban JI, et al. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial. Clin Infect Dis. 2009;48(8):1152–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Buti M, Lurie Y, Zakharova N. Extended treatment duration in chronic hepatitis C genotype 1 infected slow-responders: final results of the SUCCESS study. In: 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009). Copenhagen, Denmark; 2009.Google Scholar
  32. 32.
    Iorio A, Marchesini E, Awad T, Gluud LL. Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus. Cochrane Database Syst Rev. 2010;(1):CD004888.Google Scholar
  33. 33.
    Raptopoulou M, Tsantoulas D, Vafiadi I, et al. The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha-2b plus ribavirin treatment of naive and nonresponder chronic hepatitis C patients. J Viral Hepat. 2005;12(1):91–5.PubMedCrossRefGoogle Scholar
  34. 34.
    De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology. 2000;31(4):997–1004.PubMedCrossRefGoogle Scholar
  35. 35.
    Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010;464(7287):405–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Afdhal N. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology. 2004;126(5):1302–11.PubMedCrossRefGoogle Scholar
  37. 37.
    Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs. 2005;19(2):105–23.PubMedCrossRefGoogle Scholar
  38. 38.
    Sylvestre DL. Treating hepatitis C virus infection in active substance users. Clin Infect Dis. 2005;40 Suppl 5:S321–4.PubMedCrossRefGoogle Scholar
  39. 39.
    Sherman KE, Rouster SD, Stanford S, et al. Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with interferon-based regimens. J Infect Dis. 2010;201(5):712–9.PubMedGoogle Scholar
  40. 40.
    Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis c and treatment failure: a genome-wide association study. Gastroenterology. 2010;138(4):1338–45.PubMedCrossRefGoogle Scholar
  41. 41.
    Fleischer R, Boxwell D, Sherman KE. Nucleoside analogues and mitochondrial toxicity. Clin Infect Dis. 2004;38(8):e79–80.PubMedCrossRefGoogle Scholar
  42. 42.
    Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease ­inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature. 2003;426(6963):186–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360(18):1839–50.PubMedCrossRefGoogle Scholar
  44. 44.
    McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360(18):1827–38.PubMedCrossRefGoogle Scholar
  45. 45.
    Watashi K. Alisporivir, a cyclosporin derivative that selectively inhibits cyclophilin, for the treatment of HCV infection. Curr Opin Investig Drugs. 2010;11(2):213–24.PubMedGoogle Scholar
  46. 46.
    Paeshuyse J, Kaul A, De Clercq E, et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology. 2006;43(4):761–70.PubMedCrossRefGoogle Scholar
  47. 47.
    Nishiguchi S, Shiomi S, Nakatani S, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet. 2001;357(9251):196–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Imazeki F, Yokosuka O, Fukai K, Saisho H. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology. 2003;38(2):493–502.PubMedCrossRefGoogle Scholar
  49. 49.
    Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008;359(23):2429–41.PubMedCrossRefGoogle Scholar
  50. 50.
    Sherman KE, Andersen JW, Butt AA, Umbleja T, Alston B, Koziel MJ, Peters MG, Sulkowski M, Goodman ZD, Chung RT; for the Aids Clinical Trials Group A5178 Study Team. Sustained Long-Term Antiviral Maintenance Therapy in HCV/HIV-Coinfected patients (SLAM-C). J Acquir Immune Defic Syndr. 2010;55(5):597–605.Google Scholar
  51. 51.
    Labarga P, Vispo E, Barreiro P, et al. Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/HCV-coinfected patients with prior nonresponse or relapse. J Acquir Immune Defic Syndr. 2010;53(3):364–8.PubMedCrossRefGoogle Scholar
  52. 52.
    McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362(14):1292–303.PubMedCrossRefGoogle Scholar
  53. 53.
    Low E, Vogel M, Rockstroh J, Nelson M. Acute hepatitis C in HIV-positive individuals. AIDS Rev. 2008;10(4):245–53.PubMedGoogle Scholar
  54. 54.
    Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001;345(20):1452–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Dominguez S, Ghosn J, Valantin M, et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS. 2006;20(8):1157–61.PubMedCrossRefGoogle Scholar
  56. 56.
    Corey KE, Ross AS, Wurcel A, et al. Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin Gastroenterol Hepatol. 2006;4(10):1278–82.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of GastroenterologyMassachusetts General HospitalBostonUSA
  2. 2.Department of GastroenterologyBeth Israel Deaconess Medical CenterBostonUSA

Personalised recommendations